Stockscreener 앱 받기
0.00
100.00%
-104.91
Exact Sciences Corp 주식(EXAS)의 최신 뉴스
Exact Sciences stock trades steady as colorectal screening momentum meets earnings pressure - Ad-hoc-news.de
Exact Sciences stock advances on evidence from latest results - Ad-hoc-news.de
Patient Sues Abbott Labs, Exact Sciences in Data Theft - BankInfoSecurity
Exact Sciences stock trades steadily as revenue grows and screening portfolio expands - Ad-hoc-news.de
At Home Cancer Testing Market Size & Growth Analysis, 2026-2035 - Market Business Insights
Abbott Laboratories and Exact Sciences Corp Under Investigation for Data Breach of Patient Records - Schubert Jonckheer & Kolbe
Abbott Labs Accused Of Lax Security Over Shinyhunters Hack - Law360
Exact Sciences stock trades steady as revenue growth and screening demand support valuation - Ad-hoc-news.de
Exact Sciences stock trades near recent highs as screening demand supports revenue growth - Ad-hoc-news.de
Exact Sciences stock holds as investors await fresh numbers - AD HOC NEWS
Exact Sciences stock trades steadily as screening growth offsets guidance reset - Ad-hoc-news.de
Exact Sciences stock trades around recent range as screening revenue grows and losses narrow - Ad-hoc-news.de
Exact Sciences stock trades steady as Cologuard growth supports 2025 outlook - Ad-hoc-news.de
Abbott investigates two separate cyber incidents, says no operations affected - Reuters
Abbott raises 2026 profit forecast on strength in diagnostics, medical devices - Reuters
Abbott statement on cyber incident in Cancer Diagnostics business - Abbott
If You Invested $1,000 in Exact Sciences Corp (EXAS) - Stock Titan
Exact Sciences builds out cancer diagnostics. Operations and Nasdaq listing shape the story - ad-hoc-news.de
Exact Sciences Corp background and business model - ad-hoc-news.de
Exact Sciences stock leans on its screening base. Investors watch the U.S. testing franchise. - Ad-hoc-news.de
Exact Sciences focuses on cancer screening and long-term growth - Ad-hoc-news.de
Exact Sciences outlines long term diagnostics growth as cancer screening demand expands - ad-hoc-news.de
The Cologuard testExact Sciences leans on at-home colon cancer screening - Ad-hoc-news.de
Exact Sciences focuses on cancer diagnostics as investors track its long term growth prospects - ad-hoc-news.de
Exact Sciences Corp outlines growth ambitions as cancer screening demand expands - ad-hoc-news.de
Exact Sciences holds steady as investors await a fresh catalyst - AD HOC NEWS
Exact Sciences focuses on cancer diagnostics as investors weigh long-term growth - Ad-hoc-news.de
Exact Sciences highlights cancer screening focus as diagnostics portfolio expands - AD HOC NEWS
List of 29 Acquisitions by Abbott (Jul 2026) - Tracxn
Oncotype DX Breast Recurrence Score from Exact SciencesHow one test shapes US cancer care - AD HOC NEWS
Exact Sciences with steady analyst picture, shares trade on NASDAQ - Ad Hoc News
Exact Sciences opens the week with a clear earnings calendar, shares on NASDAQ in focus - ad-hoc-news.de
Cologuard from Exact Sciences Corp.multi-target stool DNA test reshapes home screening - Ad-hoc-news.de
Exact Sciences background and strategy, shares on NASDAQ in a diagnostics peer view - AD HOC NEWS
Exact Sciences consensus stays constructive, analysts see upside for the shares - AD HOC NEWS
Labcorp rolls out colorectal cancer screening test nationwide - MedTech Dive
Exact Sciences analyst focus on estimates, shares under Wall Street scrutiny - AD HOC NEWS
Align Technology Announces Board Leadership Transition: Kevin Conroy Named Chairman, Succeeding C. Raymond Larkin, Jr. in July 2026 - Minichart
Exact Sciences Corp (EXAS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Exact Sciences StockAnalyst consensus and valuation snapshot - AD HOC NEWS
Why Cologuard from Exact Sciences is quietly changing at-home cancer screening - AD HOC NEWS
Align Taps Growth Architect Kevin Conroy as Chairman for Next Innovation Era - BriefGlance
Exact Sciences Corp (EXAS) Institutional Confidence - TradingKey
Exact Sciences Corp (EXAS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Exact Sciences Corp (EXAS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Exact Sciences Corp (EXAS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Exact Sciences Corp (EXAS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Exact Sciences Corp (EXAS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Exact Sciences Corp (EXAS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Exact Sciences Corp. Stock (US30063P1057): shares in focus amid quiet newsflow - AD HOC NEWS
Exact Sciences Corp. Stock (US30063P1057): Technical picture in focus after recent volatility - AD HOC NEWS
Exact Sciences Corp. Stock (US30063P1057): valuation and fundamentals in focus after recent run-up - AD HOC NEWS
Mounting Evidence Backs Abbott's Cancer Diagnostics Growth Story - Yahoo Finance
Exact Sciences Corp. stock (US30063P1057): earnings momentum and cancer screening growth in focus - AD HOC NEWS
Exact Sciences (EXAS): Company Profile, Stock Price, News, Rankings - Fortune
Exact Sciences Corp stock (US30063P1057): Nasdaq-listed cancer diagnostics group steady after recent - AD HOC NEWS
Exact Sciences Corp. stock (US30063P1057): Abbott buyout clouds listing status and sector role - AD HOC NEWS
1.77%
2.25%
자본화:
|
볼륨(24시간):